Catalyst Wire Dossier Catalyst Wire Dossier

Toca 511

retroviral replicating vector expressing cytosine deaminase · Tocagen Inc.
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Toca 511, covering 2018-05-21 to 2020-03-24. Get the full timeline:

Most recent: Clinical Trial Update: Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma [Phase 2, Phase 3]

See pricing